# US 7,078,036 B2 · Modulation of cholesteryl ester transfer protein (CETP) activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,078,036 B2
- Document ID: US7078036B2
- Status: Granted
- Kind: B2
- Application number: 09/943,334
- Filed: 2001-08-30
- Published: 2004-05-06
- Granted: 2006-07-18
- Earliest claimed: 1995-05-01
- Assignees: Avant Immunotherapeutics, Inc.
- Inventors: Charles W. Rittershaus; Lawrence J. Thomas
- Web page: https://patentgrep.com/patent/US7078036B2

## CPC

- A61K 39/0012: {Lipids; Lipoproteins}
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 37/04: Immunostimulants
- C07K 14/47: from mammals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates to peptides comprising a helper T cell epitope portion and a B cell epitope portion for eliciting an immune response against endogenous cholesteryl ester transfer protein (CETP) activity, to prevent or treat cardiovascular disease, such as atherosclerosis.

## Claims

### Claim 1

A method for treating or preventing atherosclerosis in a human or animal comprising administering to said human or animal an antigenic vaccine peptide comprising a universal helper T cell epitope portion linked to a B cell epitope portion, wherein said B cell epitope portion comprises a B cell epitope of CETP.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said helper T cell epitope portion comprises a helper T cell epitope derived from an antigenic peptide selected from the group consisting of tetanus toxoid, diphtheria toxoid, pertussis vaccine, Bacile Calmette-Guerin (BCG), polio vaccine, measles vaccine, mumps vaccine, rubella vaccine, purified protein derivative of tuberculin, keyhole limpet hemocyanin, hsp70, and combinations thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said B cell epitope portion of the antigenic vaccine peptide comprises 6 to 26 consecutive amino acids of the carboxyl terminal 26 amino acids of human cholesteryl ester transfer protein (SEQ ID NO:1).

### Claim 4 (depends on 3)

The method according to claim 3, wherein the vaccine peptide comprises the amino acid sequence of SEQ ID NO:2.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the vaccine peptide comprises a dimer of the amino acid sequence of SEQ ID NO:2.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the mode of said administration of said antigenic vaccine peptide is selected from the group consisting of intraperitoneal administration, interperitoneal administration, intramuscular injection, intravenous injection, subcutaneous injection, and oral administration.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said administration is comprised of one primary dose of said antigenic vaccine peptide followed by one or more booster administrations of said vaccine peptide.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said antigenic vaccine peptide is formulated with a pharmaceutically acceptable adjuvant.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said pharmaceutically acceptable adjuvant is alum.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said antigenic vaccine peptide further comprises an amino and/or carboxyl terminal cysteine residue.